Ratings Alignment Healthcare, Inc.

Equities

ALHC

US01625V1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.83 ^USD	-1.16%		+3.02%	-20.67%

May. 08	Piper Sandler Upgrades Alignment Healthcare to Overweight From Neutral	MT
May. 03	UBS Adjusts Price Target on Alignment Healthcare to $6.50 From $8.50, Maintains Neutral Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.52 for the 2024 fiscal year.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
ALIGNMENT HEALTHCARE, INC.	-20.67%	1.31B	B-
ELEVANCE HEALTH, INC.	+14.34%	125B	A-
CIGNA	+16.34%	98.97B	B-
CENTENE CORPORATION	+4.82%	41.51B	B-
HUMANA INC.	-26.70%	40.44B	A-
MOLINA HEALTHCARE, INC.	-1.86%	20.78B	B-
PROGYNY, INC.	-25.95%	2.65B	C+
CLOVER HEALTH INVESTMENTS, CORP.	-13.87%	407M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes